Q3 Revenue Up 8.6%, EPS Up 37%; FY26 Guidance Raised and New $250M Buyback Authorized
CON has more than doubled off its 52-week low of $18.545.
Summary
Concentra beat its own trajectory with Q3 revenue of $622.1 million, up 8.6% year over year, and EPS of $0.52, up 36.8%. Adjusted EBITDA rose 17.9% to $140.2 million, expanding margin to 22.5% from 20.8%. The company raised full-year 2026 guidance to revenue of $2.360-$2.380 billion and Adjusted EBITDA of $505-$510 million, and authorized a new $250 million buyback on top of its existing program. It also declared a $0.0625 quarterly dividend and got an S&P upgrade to BB with Moody's outlook moved to positive. This is the first quarter under new CEO Matt DiCanio, who took over November 1 from Keith Newton, now executive chairman. Q3 free cash flow of $32.2 million came in below last year's $40.2 million on higher working capital use, a soft spot worth noting. The earnings call is November 6 at 9 a.m. ET.
At the time of this announcement, CON was trading at $41.91 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $18.55 to $44.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.